Daniel Hagee, OD
Optometrist · Blue Ash, OHNPI 1306391149
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,121 and has fallen 62.9% since, to $416 in 2025.
Across 69 payments — averaging $34.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Visioneering Technologies, Inc.$463
- Alcon$403
- Bausch & Lomb, A Division Of Bausch Health US, LLC$285
- Bausch & Lomb Americas Inc.$196
- Tarsus Pharmaceuticals, Inc.$191
- Coopervision Inc.$177
- plus $667 from 9 others
Across 21 payments — averaging $2649.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$56K
What the payments were for
- Speaking & faculty fees$2008%
- Food & beverage$2,18192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Visioneering Technologies, Inc. | 2 | $463 |
| Alcon | 8 | $403 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $285 |
| Bausch & Lomb Americas Inc. | 10 | $196 |
| Tarsus Pharmaceuticals, Inc. | 6 | $191 |
| Coopervision Inc. | 10 | $177 |
| Johnson & Johnson Vision Care, Inc. | 8 | $144 |
| Glaukos Corporation | 1 | $124 |
| Novartis | 6 | $120 |
| AbbVie(2 entities) | 5 | $114 |
| Harrow Eye, LLC | 4 | $74 |
| Biotissue Holdings Inc. | 2 | $37 |
| Kala Pharmaceuticals, Inc. | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BIOTRUE ONE DAY$245
- Air Optix Color$200
- DAILIES TOTAL1$200
- Precision 1$200
- BIOTRUE$123
- ULTRA$123
How this compares
$2,381 in reported general payments places this provider in the 80th percentile of 1,995 optometrist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 35 | $39,578 |
| LumiganBimatoprost | 37 | $18,538 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $7,961 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $4,186 |
| Latanoprost | 358 | $2,871 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 97 | $1,432 |
| Brimonidine Tartrate | 34 | $1,005 |
| Timolol Maleate | 113 | $796 |
| Dorzolamide Hcl | 49 | $687 |
| Prednisolone Acetate | 25 | $639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $114 | $62,30385 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,995 optometrist providers in Ohio.
Other optometrist in Blue Ash
- Mile BrujicBowling Green$1.3M
- Gregory DenaeyerColumbus$846K
- Cory LappinMontgomery$367K
- Chris SmileyColumbus$305K
- Thomas ChesterCleveland$300K
- Carly RoseCincinnati$203K
- Wendy HallierReynoldsburg$200K
- John LahrCincinnati$145K
- Erin RueffColumbus$131K
- Mary YackeyCincinnati$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.